Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan

Thursday, Feb 07, 2019

Codexis, Inc. announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an active ingredient in Beova® Tablets, a novel, once-daily treatment for overactive bladder. The product was commercially launched in Japan in November 2018.

“Our CodeEvolver® technology enabled a computational design strategy to create an enzyme that eliminates several manufacturing steps and performs in a high-pH environment.  This proprietary enzyme will now be used to streamline vibegron manufacturing,” said Codexis President and CEO John Nicols. “This agreement with KYORIN is another example of the significant value our technology brings in developing high-performing, value-added enzymes with utility from R&D to commercial-scale manufacturing. We are delighted to enter into this supply agreement with KYORIN.”



Other News